Macfarlane Group And 2 Other Leading Dividend Stocks On UK
In the last week, the United Kingdom market has been flat, though it has seen an 8.5% increase over the past year with earnings projected to grow by 15% annually in the coming years. In such a climate ...
BioSpace29d
Facing a Dearth of Big Pharma Interest, Rare Disease Players Get Creative to Fund R&D
CEO Neil McFarlane told BioSpace that Zevra has had varying funding approaches throughout the years, including royalty financing, equity, debt and M&A. “We did both mergers and acquisitions to create ...